0000912282-16-000652.txt : 20160321 0000912282-16-000652.hdr.sgml : 20160321 20160321125119 ACCESSION NUMBER: 0000912282-16-000652 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160315 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20160321 DATE AS OF CHANGE: 20160321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 161518219 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 biolife8k_031816.htm biolife8k_031816.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549

______________________________

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934


March 15, 2016
Date of report (Date of earliest event reported)

____________________________________


BIOLIFE SOLUTIONS, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware
0-18710
94-3076866
(State or Other Juris-
(Commission File No.)
(IRS Employer
diction of Incorporation)
  
Identification No.)
 
3303 Monte Villa Parkway, Bothell, WA 98021
(Address of principal executive offices, including zip code)

(425) 402-1400
(Registrant’s telephone number, including area code)

____________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
 o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
 o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
 o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 


 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On March 15, 2016, BioLife Solutions, Inc. (the "Company") approved cash bonus awards for the Company's named executive officers identified below for the fiscal year ended December 31, 2015. Other compensation for fiscal year 2015 was previously reported by the Company in the Summary Compensation Table beginning on page 58 of the Annual Report on Form 10-K for the year ended December 31, 2015 (filed with the Securities and Exchange Commission on February 25, 2016) (the "Annual Report"). As of the filing of the Annual Report, cash bonuses for the named executive officers had not been determined and, therefore, were omitted from the Summary Compensation Table included in the Annual Report. Pursuant to Item 5.02(f) of Form 8-K, the cash bonus awards and total compensation for the named executive officers for fiscal year 2015 are set forth below. No other amounts have changed.

 
Name and Principal
Positions
(a)
Year
(b)
Salary
($)
(c)
Bonus
($)
(d)
  
Stock
Awards
($)
(e)
Option
Awards
($)
(f)
All Other
Compensation
($)
(i)
Total
($)
(j)
                 
Michael Rice
2015
  
400,000
  
50,000
(1)
  
––
  
653,478
  
––
  
1,103,478
President, Chief Executive Officer and Director (8/06 – present)
2014
  
345,000
  
150,000
    
––
  
––
  
1,739
  
496,739
                             
Aby J. Mathew
2015
  
345,000
  
12,500
 (1)
  
––
  
400,516
  
––
  
758,016
Chief Technology Officer (9/00 – present)
2014
  
260,000
  
128,000
    
––
  
31,374
  
2,483
  
421,857
 
 (1)
Amount represents bonus determination made on March 15, 2016 for performance in 2015.
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 21, 2016
 
 
BIOLIFE SOLUTIONS, INC.
  
       
 
By:
/s/ Michael Rice
  
   
Michael Rice
  
   
President and Chief Executive Officer